PM 226 |
| Catalog No.GC50387 |
Potent and selective CB2 receptor agonist; BBB permeable; neuroprotective
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1949726-13-9
Sample solution is provided at 25 µL, 10mM.
Potent and selective CB2 receptor agonist (Ki = 12.8 nM; EC50 = 38.67 nM). Exhibits negligible affinity for the CB1 receptor (Ki > 40,000 nM) and no activity at the GPR55. Suppresses neuroinflammation by reducing microglial activation in a multiple sclerosis mouse model. BBB permeable; anti-inflammatory and neuroprotective.
Navarro et al (2016) Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front. Neurosci. 10 406 PMID:27679556 |Morales et al (2016) Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J.Med.Chem. 59 6753 PMID:27309150 |Gómez-Cañas et al (2016) Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol.Res. 110 205 PMID:27013280
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *